{"id":539767,"date":"2021-04-21T19:24:03","date_gmt":"2021-04-21T19:24:03","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=539767"},"modified":"2021-04-21T19:24:03","modified_gmt":"2021-04-21T19:24:03","slug":"netherton-syndrome-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-novartis-timber-pharmaceuticals-bridge-biopharma-evotec-ag-dermelix-biotherapeutics-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/netherton-syndrome-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-novartis-timber-pharmaceuticals-bridge-biopharma-evotec-ag-dermelix-biotherapeutics-and-others_539767.html","title":{"rendered":"Netherton Syndrome Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Novartis, Timber pharmaceuticals, Bridge Biopharma, Evotec AG, Dermelix Biotherapeutics and Others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Netherton Syndrome Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Novartis, Timber pharmaceuticals, Bridge Biopharma, Evotec AG, Dermelix Biotherapeutics and Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" alt=\"Netherton Syndrome Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Novartis, Timber pharmaceuticals, Bridge Biopharma, Evotec AG, Dermelix Biotherapeutics and Others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Netherton Syndrome Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><strong>Netherton Syndrome<\/strong> is a rare disorder that is inherited as an autosomal recessive trait. The disorder is caused due to the mutation in the SPINK5 gene located on chromosome 5 which is responsible for encoding proteins that serve as the break on the activity of certain proteases in the skin protein. This disorder mainly affects the immune system, skin, and hair of an individual and is characterized by elevated IgE levels, scaling skin, hair anomalies, and increased susceptibility to atopic eczema. The syndrome is estimated to affect 1 in 200,000 newborn.<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s,<strong>&nbsp;&ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/netherton-syndrome-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Netherton Syndrome Pipeline<\/a> Insight, 2021,&rdquo;<\/strong>&nbsp;report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Netherton Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of Netherton Syndrome Companies are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Novartis<\/li>\n<li>Timber pharmaceuticals<\/li>\n<li>Bridge Biopharma<\/li>\n<li>Evotec AG<\/li>\n<li>Dermelix Biotherapeutics<\/li>\n<li>Krystal Biotech<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/netherton-syndrome-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/netherton-syndrome-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s Netherton Syndrome Report covers around 6+ products under different phases of clinical development like:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Late stage products (Phase II\/III)<\/li>\n<li>Mid-stage products (Phase II)<\/li>\n<li>Early-stage product (Phase I) along with the details of<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<li>Route of Administration<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/netherton-syndrome-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Netherton Syndrome Therapies<\/a> are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <\/strong><strong>LM 030<\/strong><\/li>\n<li>Isotretinoin<\/li>\n<li>BBP-561<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/netherton-syndrome-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/netherton-syndrome-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Current Netherton Syndrome Treatment<\/strong><strong> Scenario and Netherton Syndrome Emerging Therapies<\/strong><strong>:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>How many companies are developing Netherton Syndrome drugs?<\/li>\n<li>How many Netherton Syndrome drugs are developed by each company?<\/li>\n<li>How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Netherton Syndrome?<\/li>\n<li>What are the key collaborations (Industry&ndash;Industry, Industry&ndash;Academia), Mergers and acquisitions, licensing activities related to the Netherton Syndrome therapeutics?<\/li>\n<li>What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?<\/li>\n<li>What are the clinical studies going on for Netherton Syndrome and their status?<\/li>\n<li>What are the key designations that have been granted to the emerging drugs?<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/netherton-syndrome-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/netherton-syndrome-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">Introduction<\/p>\n<p style=\"text-align: justify;\">Executive Summary<\/p>\n<p style=\"text-align: justify;\">Netherton Syndrome: Overview<\/p>\n<p style=\"text-align: justify;\">Pipeline Therapeutics<\/p>\n<ul style=\"text-align: justify;\">\n<li>Comparative Analysis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">Netherton Syndrome &ndash; DelveInsight&rsquo;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">Netherton Syndrome Collaboration Deals<\/p>\n<p style=\"text-align: justify;\">Late Stage Products (Phase II\/III)<\/p>\n<ul style=\"text-align: justify;\">\n<li>Comparative Analysis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">LM030: Novartis<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Mid Stage Products (Phase II)<\/p>\n<ul style=\"text-align: justify;\">\n<li>Comparative Analysis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Isotretinoin: Timber Pharmaceuticals<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Early Stage Products (Phase I)<\/p>\n<ul style=\"text-align: justify;\">\n<li>Comparative Analysis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Drug Name: Company Name<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Inactive Products<\/p>\n<p style=\"text-align: justify;\">Netherton Syndrome Key Companies<\/p>\n<p style=\"text-align: justify;\">Netherton Syndrome Key Products<\/p>\n<p style=\"text-align: justify;\">Netherton Syndrome- Unmet Needs<\/p>\n<p style=\"text-align: justify;\">Netherton Syndrome- Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">Netherton Syndrome- Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify;\">Netherton Syndrome Analyst Views<\/p>\n<p style=\"text-align: justify;\">Netherton Syndrome Key Companies<\/p>\n<p style=\"text-align: justify;\">Appendix<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Detailed TOC: https:\/\/www.delveinsight.com\/sample-request\/netherton-syndrome-pipeline-insight<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;DelveInsight<\/strong><br \/> DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=netherton-syndrome-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-novartis-timber-pharmaceuticals-bridge-biopharma-evotec-ag-dermelix-biotherapeutics-and-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/netherton-syndrome-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/netherton-syndrome-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/netherton-syndrome-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=netherton-syndrome-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-novartis-timber-pharmaceuticals-bridge-biopharma-evotec-ag-dermelix-biotherapeutics-and-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Netherton Syndrome Pipeline Netherton Syndrome is a rare disorder that is inherited as an autosomal recessive trait. The disorder is caused due to the mutation in the SPINK5 gene located on chromosome 5 which is responsible for encoding proteins that &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/netherton-syndrome-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-novartis-timber-pharmaceuticals-bridge-biopharma-evotec-ag-dermelix-biotherapeutics-and-others_539767.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-539767","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/539767","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=539767"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/539767\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=539767"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=539767"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=539767"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}